Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Omvik

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
American Heart Journal|December 17, 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Kidney International|February 12, 2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE studyAud Høieggen, Michael H Alderman, Sverre E Kjeldsen, et al.
Journal of Hypertension|August 18, 2004
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudyHans Ibsen, Kristian Wachtell, Michael H Olsen, et al.
JAMA|September 24, 2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudySverre E Kjeldsen, Björn Dahlöf, Richard B Devereux, et al.
Blood Pressure|March 18, 2005
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE studyHenrik M Reims, Suzanne Oparil, Sverre E Kjeldsen, et al.
Journal of Hypertension|March 6, 2009
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Hypertension (Dallas, Tex. : 1979)|January 19, 2005
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Circulation|April 20, 2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) studyGiovanni de Simone, Kristian Wachtell, Vittorio Palmieri, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars H Lindholm, Hans Ibsen, Björn Dahlöf, et al.
Blood Pressure|December 17, 2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension studySverre E Kjeldsen, Richard B Devereux, Darcy A Hille, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
American Heart Journal|December 17, 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Kidney International|February 12, 2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE studyAud Høieggen, Michael H Alderman, Sverre E Kjeldsen, et al.
Journal of Hypertension|August 18, 2004
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudyHans Ibsen, Kristian Wachtell, Michael H Olsen, et al.
JAMA|September 24, 2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudySverre E Kjeldsen, Björn Dahlöf, Richard B Devereux, et al.
Blood Pressure|March 18, 2005
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE studyHenrik M Reims, Suzanne Oparil, Sverre E Kjeldsen, et al.
Journal of Hypertension|March 6, 2009
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Hypertension (Dallas, Tex. : 1979)|January 19, 2005
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Circulation|April 20, 2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) studyGiovanni de Simone, Kristian Wachtell, Vittorio Palmieri, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars H Lindholm, Hans Ibsen, Björn Dahlöf, et al.
Blood Pressure|December 17, 2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension studySverre E Kjeldsen, Richard B Devereux, Darcy A Hille, et al.
Pageof 4